Loading
A phase 1/2 trial of Farletuzumab-exatecan in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07744763 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 260 participants planned, started 2025-03-28 and due to reach its primary completion in 2027-03-28. Interventions recorded: SYS6041.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/